$283.85+0.98%Close 16 Nov 2026 · Market value $65.13B
In its results release of 5 Nov 2026 (Q1 FY2027), Cardinal Health gave 2 forecasts in figures, among them EPS (adjusted) of $12.80 to $13.00 for FY2027.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q1 FY2027 results, 5 Nov 2026
| Measure | Period | Guidance | As stated |
|---|
| EPS · Adjusted · Raised | FY2027 | $12.80 to $13.00 | Cardinal Health raises fiscal year 2027 non-GAAP EPS guidance 2 to $12.80 to $13.00, 17% to 19% growth 3 from its FY26 ex-tariff refund baseline and 14% to 15% growth from reported FY26 results |
|---|
| EPS growth · Adjusted | FY2027 | +17% to +19% | Cardinal Health raises fiscal year 2027 non-GAAP EPS guidance 2 to $12.80 to $13.00, 17% to 19% growth 3 from its FY26 ex-tariff refund baseline and 14% to 15% growth from reported FY26 results |
|---|
Source: the company's earnings release.
Guidance against results above 1 · within 1 · below 0
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| EPS growth · Adjusted | FY2027 | +17% to +19% | Raised once | — | To come |
|---|
| EPS · Adjusted | FY2027 | $12.80 to $13.00 | Raised once | — | To come |
|---|
| Free cash flow · Adjusted | FY2027 | $3.50B to $4.00B | Given once | — | To come |
|---|
| Capital expenditures | FY2027 | $700M | Given once | — | To come |
|---|
| Tax rate · Adjusted | FY2027 | 19% to 20% | Given once | — | To come |
|---|
| EPS · Adjusted | FY2026 | $10.70 to $10.80 | Raised 4 times | $11.26 | Above the range |
|---|
| Capital expenditures | FY2026 | $600M to $650M | Raised once | $649M | Within the range |
|---|
CAH in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.